Download BLOOD PRODUCT FACT SHEET Antihemophilic Factor / von

BLOOD PRODUCT FACT SHEET
Antihemophilic Factor / von Willebrand Factor Complex
Other Names
Humate P®
Pre-Transfusion
Sample
x Not Required
Approval
Requirements
Product must be ordered by clinical hematologist or Hemophilia Clinic Nurse
Practitioner with required privileges.
Product Description
Stable, purified, sterile, lyophilized concentrate of antihemophilic factor and von
Willebrand factor prepared from human plasma. Heat treated to reduce viral
transmission. Contains no preservatives.
Supplied in vial sizes (Factor VIII / von Willebrand Factor):
 200-300 IU / 360-840 IU
 400-600 IU / 720-1680 IU
 810-1200 IU / 1440-3360 IU
One International Unit (IU) Factor VIII or von Willebrand Factor:Ristocetin
Cofactor (vWF:RCo) is approximately equal to the level of Factor VIII or vWF:RCo
found in 1 mL of fresh plasma.
Reconstituted and filtered into a syringe in Transfusion Medicine.
Clinical Indications


o Blood Group
o Group & Screen
o Crossmatch
Treatment of spontaneous and trauma-induced bleeding episodes in
severe von Willebrand disease (vWD), or in mild/moderate vWD where use
of desmopressin is inadequate.
To prevent excessive bleeding during and after surgery in patients with
vWD

Contraindications


None known.
Caution is advised in patients with known allergic reactions to constituents of
the preparation.
Risks
Allergic and anaphylactic reactions.
Intravascular hemolysis with decreasing hematocrit in patients of blood groups A,
B and AB when treated with large doses of Humate P®.
Thrombotic events in von Willebrand disease patients with known risk factors to
thrombosis.
Factor VIII inhibitor formation.
As Humate P® is a plasma product there is a risk for transmission of infection.
Humate P® should be given to a pregnant woman only if clearly needed.
Dosage
Many patients carry a Factor First card with pertinent information about their
prescribed therapy.
Consult with the Hematologist-on-call for dosing and prescribing guidelines
The dosage must be individualized according to the needs of the patient.
The product must be ordered in vWF:RCo units(Ristocetin cofactor units), not
Factor VIII units.
The nearest combination of whole vials must be used to deliver the prescribed
dose.
Administration
Visually inspect for particulate matter and discolouration prior to administration.
Refer to:
Disclaimer Message
TR.05.18
Transfusion Manual
Page 1 of 2
The following information, i.e. guideline/educational material/policy or procedure, has been developed for use only within BC Children's Hospital (BC Children's) and BC Women's Hospital and Health Centre (BC Women's).
Agencies other than BC Children's or BC Women's should use this information as a guideline for reference purposes only. All materials are the property of BC Children's and BC Women's and may only be reprinted in whole or
in part with our expressed permission. Contact [email protected] with questions.
Date/Time Generated
Generated By
Nov 02, 2016 10:14
Anonymous
BLOOD PRODUCT FACT SHEET
Antihemophilic Factor / von Willebrand Factor Complex
Administering Medications Using IV Push Method
Product monograph
Administer:

By intravenous injection only

At room temperature

Through a separate injection site

Inject slowly to a maximum rate of 4 mL/minute.


Compatible Solution
The manufacturer does not recommend any compatible fluids.
Flush the line before and after administration with 0.9% Normal Saline only.
Do not mix with other medicinal products or intravenous admixtures.
Infusion Rates
Maximum infusion rate is 4 mL/minute.
Monitoring
Observe patient for signs and symptoms of a transfusion reaction.
In the event of a suspected transfusion reaction, refer to Transfusion Reaction
Procedure & Quick Reference guide and complete Transfusion Reaction Report
Form.
EVALUATE effectiveness of treatment.
Storage Conditions
Stored at room temperature, not to exceed 25 C.
Home storage of Humate-P may vary from in hospital storage and does not apply
in the hospital situation.
For reconstituted product:
 Store at room temperature
 Administer within 3 hours of reconstitution.

Return product and Transfusion Record to Transfusion Medicine within 20
minutes from time of issue if there are any delays in administration.
 Do not refrigerate or store on nursing unit.
References
Product Monograph Humate-P: CSL Behring Canada Inc, January 2013.
Retrieved from:
http://www.cslbehring.ca/docs/783/911/English_Humate%20P_PM.pdf
Disclaimer Message
TR.05.18
Transfusion Manual
Page 2 of 2
The following information, i.e. guideline/educational material/policy or procedure, has been developed for use only within BC Children's Hospital (BC Children's) and BC Women's Hospital and Health Centre (BC Women's).
Agencies other than BC Children's or BC Women's should use this information as a guideline for reference purposes only. All materials are the property of BC Children's and BC Women's and may only be reprinted in whole or
in part with our expressed permission. Contact [email protected] with questions.
Date/Time Generated
Generated By
Nov 02, 2016 10:14
Anonymous